2005
DOI: 10.1055/s-2005-837706 View full text |Buy / Rent full text
|
|

Abstract: Neuroendocrine tumors of the thymus are potentially aggressive tumors. Radical resection is the treatment of choice. The encouraging results obtained by administration of Octreotide LAR in two of our patients warrant further investigation.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
3
1
0
4
0

Year Published

2008
2008
2021
2021

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

0
4
0
Order By: Relevance
“…2,26,27,31 Radiotherapy is widely used 4 although its benefit is controversial. 3,36,37 Treatment with somatostatin analogues is common, but only a few reports address the response to octreotide, 22,23,25,31,34 stating progression-free intervals between 3 and 84 months.…”
Section: Discussionmentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 100,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…2,26,27,31 Radiotherapy is widely used 4 although its benefit is controversial. 3,36,37 Treatment with somatostatin analogues is common, but only a few reports address the response to octreotide, 22,23,25,31,34 stating progression-free intervals between 3 and 84 months.…”
Section: Discussionmentioning
“…[5,15] Recently, antitumor effect of long acting octreotide on thymic carcinoids was reported. [16–18] Octreotide is a synthetic analog of somatostatin with a similar spectrum of actions but a longer biological half-life. It has been proven to have antitumor effects indirectly by inhibiting growth factors like vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and the growth hormone (GH)/insulin-like growth factor-I (IGF-I) axis.…”
Section: Discussionmentioning
“…The role of this therapy in the treatment of thymic carcinoids requires further investigation. Dosios and colleagues reported encouraging results in two patients with neuroendocrine thymic tumours treated by octreotide LAR [ 12 ].…”
Section: Discussionmentioning